{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:45:46Z","timestamp":1793277946909,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["NCT02783300"],"award-info":[{"award-number":["NCT02783300"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.annonc.2025.08.3757","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T11:41:17Z","timestamp":1757504477000},"page":"1480-1491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers"],"prefix":"10.1016","volume":"36","author":[{"given":"M.M.","family":"Gounder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Martin-Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-2191","authenticated-orcid":false,"given":"G.S.","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.S.","family":"Lossos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.W.","family":"Rasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"McKean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.L.","family":"Opdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6414-6998","authenticated-orcid":false,"given":"J.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.P.","family":"Vermaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zajac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-7495","authenticated-orcid":false,"given":"F.","family":"Gonzalez Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-3801","authenticated-orcid":false,"given":"B.E.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Barbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Parasrampuria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Postel-Vinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"94","key":"10.1016\/j.annonc.2025.08.3757_bib1","doi-asserted-by":"crossref","first-page":"36705","DOI":"10.18632\/oncotarget.26404","article-title":"Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer","volume":"9","author":"Shailesh","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.annonc.2025.08.3757_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1874467212666190215112915","article-title":"Targeting chromatin remodeling for cancer therapy","volume":"12","author":"Kaur","year":"2019","journal-title":"Curr Mol Pharmacol"},{"issue":"15","key":"10.1016\/j.annonc.2025.08.3757_bib3","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1038\/sj.emboj.7601794","article-title":"Low levels of miR-92b\/96 induce PRMT5 translation and H3R8\/H4R3 methylation in mantle cell lymphoma","volume":"26","author":"Pal","year":"2007","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.annonc.2025.08.3757_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molcel.2005.04.003","article-title":"Arginine methylation an emerging regulator of protein function","volume":"18","author":"Bedford","year":"2005","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.annonc.2025.08.3757_bib5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s42003-020-01157-z","article-title":"PRMT5 promotes DNA repair through methylation of 53BP1 and is regulated by Src-mediated phosphorylation","volume":"3","author":"Hwang","year":"2020","journal-title":"Commun Biol"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2025.08.3757_bib6","doi-asserted-by":"crossref","first-page":"v159","DOI":"10.1093\/annonc\/mdz244","article-title":"METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumors","volume":"30","author":"Siu","year":"2019","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.08.3757_bib7","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/psp4.12882","article-title":"PK\/PD model-informed dose selection for oncology phase I expansion: case study based on PF-06939999, a PRMT5 inhibitor","volume":"12","author":"Guo","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.annonc.2025.08.3757_bib8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"issue":"20","key":"10.1016\/j.annonc.2025.08.3757_bib9","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1128\/MCB.00923-08","article-title":"Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells","volume":"28","author":"Wang","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.annonc.2025.08.3757_bib10","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1101\/gad.606110","article-title":"Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency","volume":"24","author":"Tee","year":"2010","journal-title":"Genes Dev"},{"issue":"17","key":"10.1016\/j.annonc.2025.08.3757_bib11","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1101\/gad.219899.113","article-title":"Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery","volume":"27","author":"Bezzi","year":"2013","journal-title":"Genes Dev"},{"key":"10.1016\/j.annonc.2025.08.3757_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112252","article-title":"Targeting protein arginine methyltransferase 5 in cancers: roles, inhibitors and mechanisms","volume":"144","author":"Chen","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.annonc.2025.08.3757_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108790","article-title":"Role of protein arginine methyltransferase 5 in human cancers","volume":"114","author":"Xiao","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.annonc.2025.08.3757_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/10732748211050583","article-title":"Clinicopathological and prognostic significance of PRMT5 in cancers: a system review and meta-analysis","volume":"28","author":"Liang","year":"2021","journal-title":"Cancer Control"},{"issue":"15","key":"10.1016\/j.annonc.2025.08.3757_bib15","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1093\/nar\/gkp516","article-title":"PRMT5 is required for cell-cycle progression and p53 tumor suppressor function","volume":"37","author":"Scoumanne","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.08.3757_bib16","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1038\/s41598-018-28002-y","article-title":"Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing","volume":"8","author":"Gerhart","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.annonc.2025.08.3757_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/genes8020082","article-title":"Targeting MDM4 splicing in cancers","volume":"8","author":"Bardot","year":"2017","journal-title":"Genes (Basel)"},{"issue":"12","key":"10.1016\/j.annonc.2025.08.3757_bib18","first-page":"5864","article-title":"MDM4 alternative splicing and implication in MDM4 targeted cancer therapies","volume":"11","author":"Wu","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"12","key":"10.1016\/j.annonc.2025.08.3757_bib19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.tibs.2011.09.001","article-title":"Versatility of PRMT5-induced methylation in growth control and development","volume":"36","author":"Karkhanis","year":"2011","journal-title":"Trends Biochem Sci"},{"issue":"21","key":"10.1016\/j.annonc.2025.08.3757_bib20","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1128\/MCB.24.21.9630-9645.2004","article-title":"Human SWI\/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes","volume":"24","author":"Pal","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"6278","key":"10.1016\/j.annonc.2025.08.3757_bib21","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"issue":"6278","key":"10.1016\/j.annonc.2025.08.3757_bib22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"issue":"1-2","key":"10.1016\/j.annonc.2025.08.3757_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.mce.2013.09.006","article-title":"Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma","volume":"386","author":"Zhou","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"10.1016\/j.annonc.2025.08.3757_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009600","article-title":"MTA cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP loss tumors","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2025.08.3757_bib25","series-title":"Merck Sharp &","year":"2024"},{"issue":"1","key":"10.1016\/j.annonc.2025.08.3757_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13046-024-03270-x","article-title":"PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands","volume":"44","author":"Mishra","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"issue":"49","key":"10.1016\/j.annonc.2025.08.3757_bib27","doi-asserted-by":"crossref","first-page":"35534","DOI":"10.1074\/jbc.M113.510669","article-title":"Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing","volume":"288","author":"Chung","year":"2013","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.annonc.2025.08.3757_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.5858\/2009-0527-RS.1","article-title":"Adenoid cystic carcinoma","volume":"135","author":"Jaso","year":"2011","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.annonc.2025.08.3757_bib29","doi-asserted-by":"crossref","first-page":"206","DOI":"10.14639\/0392-100X-N1379","article-title":"Adenoid cystic carcinoma. An indolent but aggressive tumour. Part A: from aetiopathogenesis to diagnosis","volume":"41","author":"Cant\u00f9","year":"2021","journal-title":"Acta Otorhinolaryngol Ital"},{"issue":"12","key":"10.1016\/j.annonc.2025.08.3757_bib30","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1038\/s41375-019-0489-6","article-title":"PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K\/AKT in lymphoma cells","volume":"33","author":"Zhu","year":"2019","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.annonc.2025.08.3757_bib31","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors","volume":"29","author":"Vieito","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2025.08.3757_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102961","article-title":"A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations","volume":"9","author":"Rodon","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.annonc.2025.08.3757_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107390","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes","volume":"134","author":"Haque","year":"2023","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.annonc.2025.08.3757_bib34","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1158\/2767-9764.CRC-23-0239","article-title":"Antitumor effects of PRMT5 inhibition in sarcomas","volume":"3","author":"Verbeke","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"10","key":"10.1016\/j.annonc.2025.08.3757_bib35","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.celrep.2018.08.002","article-title":"PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes","volume":"24","author":"Hamard","year":"2018","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.annonc.2025.08.3757_bib36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.08.018","article-title":"Coordinated splicing of regulatory detained introns within oncogenic transcripts creates an exploitable vulnerability in malignant glioma","volume":"32","author":"Braun","year":"2017","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.annonc.2025.08.3757_bib37","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.annonc.2025.08.3757_bib38","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.08.3757_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116947","article-title":"Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5\/MTA inhibitors","volume":"71","author":"Smith","year":"2022","journal-title":"Bioorg Med Chem"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425046964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425046964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:59:21Z","timestamp":1777582761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425046964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0923753425046964"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.08.3757","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.08.3757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 GSK. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}